Muge Buyukaksoy

Dr. Muge Buyukaksoy

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DHDenizcan Hasturk
Denizcan Hasturk
SESelin Akturk Esen
Selin Akturk Esen
EŞEnes Seyda Şahiner
Enes Seyda Şahiner
ÖEÖzcan EREL
Özcan EREL
SNsalim neselioglu
salim neselioglu
DUDoğan Uncu
Doğan Uncu
In our study, we determined the changes in the oxidative stress (OxS) biomarkers, thiol-disulfide (TD) homeostasis and ischemia-modified albumin (IMA) levels, in patients diagnosed with ovarian carcinoma before and after chemotherapy. We will examine the indirect effects of chemotherapy on OxS and antioxidant capacity by measuring changes in these blood biomarkers and compare the results with those of the healthy control group. This case–control study, which was conducted in a single-center, prospective design, included 42 patients diagnosed with ovarian cancer and 51 healthy volunteers. Venous blood samples were taken from all participants after 8 h of fasting, their serum was separated, and the serum total thiol, native thiol, disulfide, and IMA values were measured. In the comparison of the blood samples taken before the chemotherapy treatment of the patient group with the healthy control group, the native thiol (p < 0.001), total thiol (p < 0.001), and native thiol/total thiol (p < 0.001) values were found to be statistically significantly lower, and the disulfide (p = 0.001), disulfide/native (p < 0.001), and disulfide/total thiol (p < 0.001) levels were found to be statistically significantly greater. In the patient group diagnosed with ovarian cancer, a statistically significant difference was detected between the measurements of cancer antigen-125 (CA-125) (p < 0.001), native thiol (p = 0.019), and total thiol (p = 0.025) values at the 0th month before chemotherapy treatment and the third month after chemotherapy treatment. In the group that received adjuvant chemotherapy after the operation, the native thiol (p = 0.035), total thiol (p = 0.043), disulfide/native thiol (p = 0.035), disulfide total thiol (p = 0.035), native thiol/total thiol (p = 0.035) and IMA (p = 0.026) values were statistically significantly different between the diagnosis and third-month values. Our study suggests that TD homeostasis may be an important guide in terms of disease progression, complications during chemotherapy treatment, appropriate dose reductions, and modifications in chemotherapy depending on the toxicities experienced and the goals of the treatment.

10 May 2024 in Medicine
Verified
Journal Article
Open access
DHDenizcan Hasturk
Denizcan Hasturk
SESelin Akturk Esen
Selin Akturk Esen
MBMuge Buyukaksoy
Muge Buyukaksoy
BCBurak Civelek
Burak Civelek
ISIsmet Seven
Ismet Seven
DUDoğan Uncu
Doğan Uncu
Colon lymphoma is a rare type of gastrointestinal lymphoma and represents 0.2% to –1.2% of all primary colon cancers. This study aimed to retrospectively examine the general characteristics, treatment methods, and survival characteristics of patients with colon lymphoma who were followed-up at our center. This retrospective study included patients diagnosed with colon lymphoma who were followed up at Ankara Numune Training and Research Hospital and Ankara Bilkent City Hospital between December 2005 and June 2023. Clinicopathological features, radiological findings, treatments, and modalities of patients were obtained from their medical records. Fourteen patients with primary colon lymphoma were included in the study. Thirteen patients (92.9%) were diagnosed with diffuse large B-cell lymphoma. The median age of the patients was 55 (28–84) years. The tumor location was the terminal ileum/cecum in 50% of the patients. At the time of diagnosis, 10 patients (7 with stage 1E-2E disease, 2 with stage 3E disease, and 1 with stage 4E disease due to tumor obstruction) underwent surgery. Twelve patients received chemotherapy (6 patients as adjuvant and 6 patients as first-line treatment). The median overall survival (OS) was 10 years (0.1–21.5) years, the 5-year median OS was 71%, and the 10-year median OS was 53%. Primary colon lymphoma is a rare disease and its optimal treatment is not clearly defined. The primary treatment for primary colon lymphoma is a combination of surgery and chemotherapy. A clear consensus on the treatment can be established through prospective studies.

27 September 2025 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
AAArif Akyildiz
Arif Akyildiz
BYBetul Gok Yavuz
Betul Gok Yavuz
RIRashad Ismayilov
Rashad Ismayilov
MBMuge Buyukaksoy
Muge Buyukaksoy
ESEmine Sena Sözen
Emine Sena Sözen
AKAhmed Omar Kaseb
Ahmed Omar Kaseb

29 March 2024 in Medicine
Verified
Journal Article
Open access
SESelin Akturk Esen
Selin Akturk Esen
SKSefika Karabulut
Sefika Karabulut
MBMuge Buyukaksoy
Muge Buyukaksoy
GCGulnaz Kurt Cevik
Gulnaz Kurt Cevik
FCFurkan Ceylan
Furkan Ceylan
DUDoğan Uncu
Doğan Uncu
The prognostic role of fibroblast growth factor 11 (FGF11) has only been reported in cancers such as nasopharyngeal carcinoma and prostate cancer. The role of FGF11 in breast cancer is not fully known. It was aimed to compare FGF11 expression levels in de novo metastatic hormone receptor-positive, human epidermal reseptor-2-negative breast tumor tissue and healthy breast tissue and investigate the effect of the FGF11 expression on survival in breast cancer patients. To determine the FGF11 expression rate, breast tumor tissue of breast cancer patients diagnosed by breast biopsy and healthy breast tissue of healthy individuals who underwent breast biopsy due to benign lesions were used. The study population included 38 breast cancer patients and 24 healthy controls. The number of patients with a FGF11 expression level score of 1 (15.8% vs 12.5%), score of 2 (18.4% vs 12.5%), and score of 3 (31.6% vs 0%) was significantly higher in the patient group compared to the healthy control group. The median overall survival and progression-free survival were numerically better in the group with a FGF11 expression score of 0 to 1 than the group with a FGF11 expression score of 2 and 3, but this difference was not statistically significant. FGF11 may be a predictive marker for breast cancer formation. Additionally, with new FGF11-targeted treatment agents to be developed, endocrine resistance may be reduced, and better survival results may be achieved in hormone receptor-positive, human epidermal reseptor-2-negative breast cancer.

22 December 2023 in Akademik Gastroenteroloji Dergisi
Verified
Journal Article
Open access
PDF file
AAAli Atay
Ali Atay
YÖYasemin Özderi̇n Özi̇n
Yasemin Özderi̇n Özi̇n
DGDilara Turan Gökçe
Dilara Turan Gökçe
MBMuge Buyukaksoy
Muge Buyukaksoy
GDGamze Demi̇rel
Gamze Demi̇rel
EAEmin Altiparmak
Emin Altiparmak
Giriş ve Amaç: İmmünmodülatör ajanlar inflamatuvar bağırsak hastalığı tedavisinde önemli köşe taşlarından olup pürin sentezini inhibe eden azatioprin ve metotreksat başlıca kullanılmakta olan ajanlardandır. Bu ajanların yanıtsızlık veya yan etki profilleri nedeni ile her zaman efektif dozda kullanılmaları mümkün olmayabilir. Çalışmamızda immünmodülatör ajanların güvenlik profilinin değerlendirilmesi amacı ile tedavi kesilmesini gerektirecek yan etkilerin derlendiği 23 yıllık deneyimin sunulması amaçlandı. Gereç ve Yöntem: 1999-2022 yılları arasında inflamatuvar bağırsak hastalığı tanısı ile takipli olan, halihazırda anti-tümör nekrozis faktör tedavisi almakta olup tedavi dozunda azatioprin veya metotreksat kullanım geçmişi olan hastalarda tedavi kesilmesini gerektirecek yan etkiler geriye dönük olarak incelendi. İmmünmodülatör ajanları tedavi dozunda almamış olan hastalar ile tedavi kesilmesini gerektirmeyecek durumların gözlendiği hastalar dışlandı. Bulgular: Çalışma grubu 310 Crohn hastalığı ve 100 ülseratif koliti olan hasta olmak üzere 410 hastadan oluşuyordu. 325 hastada azatioprin, 85 hastada metotreksat kullanım öyküsü mevcuttu. Hastaların ortalama yaşı 42.6 ± 13.4 yıl olup 257’si erkek (%62.6) idi. Azatioprin kullanım süresi Crohn hastalarında 4.2 ± 3.5 yıl, ülseratif kolit olan hastalarda 3.0 ± 2.6 yıl idi. Azatioprin kullanmış olan hastaların 18’inde (%5.5), metotreksat kullanmış olan hastaların 6’sında (%7) kesilmesini gerektirecek yan etkiler geliştiği tespit edildi ve yan etkilerin tamamı 2. derece yan etkilerden oluşmaktaydı. İmmünmodülatör ajanların tedavi bırakmayı gerektiren yan etki sıklığında iki grup arasında anlamlı fark saptanmadı (p: 0.59). Her iki tedavi grubunda da takip süresince tedavi ilişkili hematolojik veya solid organ malignitesi saptanmadı. Sonuç: İnflamatuvar bağırsak hastalığı tanısı ile takipli hastalarda azatioprin ve metotreksat yan etki profili göz önüne alındığında iki grup arasında anlamlı fark olmayıp tedavi süresince yakın takip ile güvenli kullanılabilecek ajanlardır.

Verified
Journal Article
Open access
PDF file
MBMuge Buyukaksoy
Muge Buyukaksoy
SESelin Akturk Esen
Selin Akturk Esen
NTNesrin Turhan
Nesrin Turhan
EŞEnes Seyda Şahiner
Enes Seyda Şahiner
İEİmdat Eroglu
İmdat Eroglu
DUDoğan Uncu
Doğan Uncu
Background/Objective: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy with limited therapeutic options and poor survival outcomes. Recent advances in molecular oncology have highlighted the significance of isocitrate dehydrogenase 1 (IDH1) mutations as potential therapeutic targets. However, data on the prevalence and prognostic implications of IDH1 mutations in patients with iCCA are scarce. This study aimed to retrospectively investigate the IDH1 mutation rate, histopathological features, and survival outcomes of patients with iCCA. Methods: We retrospectively analyzed 88 patients diagnosed and treated between 2005 and 2025 at two tertiary oncology centers. Clinical, pathological, and survival data were obtained from the institutional oncology archives and national population databases. IDH1 mutation status was evaluated using polymerase chain reaction and next-generation sequencing of paraffin-embedded tissue samples. Results: A total of 88 patients with iCCA were included, with a median age of 62 years, and 62.5% were male. Abdominal pain was the most common presenting symptom (67%). The most frequent stages at diagnosis were stage IB and stage IIIB (22.7% each). Histopathologically, the small-duct subtype (55.7%), nodular morphology (67.0%), and solitary tumors (79.5%) predominated. IDH1 mutation was detected in 2.3% of patients. Curative surgery was performed in 78.2% of cases and was more common in early-stage disease. Gemcitabine–capecitabine was the most frequently used adjuvant regimen, whereas gemcitabine–cisplatin was the most common palliative treatment regimen. Median overall survival differed significantly by albumin-bilirubin (ALBI) grade, with 40.1, 11.1, and 4.4 months for grades 1, 2, and 3, respectively (p < 0.001). Conclusions: In this multicenter cohort, iCCA was characterized by diverse clinicopathological features and treatment approaches. Surgical resection remains the main treatment modality for patients with localized disease, whereas systemic therapies are more frequently used in advanced stages. The findings highlight the prognostic relevance of baseline clinical and biochemical characteristics and may improve risk stratification in patients with iCCA.